Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 48.25 Billion KRW | 624.12% |
| 2022 | 6.66 Billion KRW | -41.92% |
| 2021 | 11.47 Billion KRW | -26.86% |
| 2020 | 15.68 Billion KRW | 127.07% |
| 2019 | 6.9 Billion KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | -100.0% |
| 2015 | 2 Billion KRW | -50.0% |
| 2014 | 4 Billion KRW | -33.33% |
| 2013 | 6 Billion KRW | -40.0% |
| 2012 | 10 Billion KRW | -64.91% |
| 2011 | 28.5 Billion KRW | -33.33% |
| 2010 | 42.75 Billion KRW | 35.17% |
| 2009 | 31.62 Billion KRW | -5.13% |
| 2008 | 33.33 Billion KRW | 441.03% |
| 2007 | 6.16 Billion KRW | -36.86% |
| 2006 | 9.75 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 40.2 Billion KRW | 18.88% |
| 2024 Q1 | 33.82 Billion KRW | -29.91% |
| 2023 Q3 | 4.42 Billion KRW | -19.51% |
| 2023 Q4 | 48.25 Billion KRW | 989.51% |
| 2023 Q1 | 4.7 Billion KRW | -29.43% |
| 2023 Q2 | 5.5 Billion KRW | 17.01% |
| 2023 FY | 48.25 Billion KRW | 624.12% |
| 2022 Q3 | 7.72 Billion KRW | -35.56% |
| 2022 Q4 | 6.66 Billion KRW | -13.69% |
| 2022 FY | 6.66 Billion KRW | -41.92% |
| 2022 Q2 | 11.98 Billion KRW | 5.21% |
| 2022 Q1 | 11.38 Billion KRW | -0.75% |
| 2021 Q4 | 11.47 Billion KRW | -8.68% |
| 2021 Q2 | 12.93 Billion KRW | -10.54% |
| 2021 FY | 11.47 Billion KRW | -26.86% |
| 2021 Q3 | 12.56 Billion KRW | -2.86% |
| 2021 Q1 | 14.45 Billion KRW | -7.84% |
| 2020 Q3 | 16.02 Billion KRW | 150.95% |
| 2020 FY | 15.68 Billion KRW | 127.07% |
| 2020 Q1 | 6.45 Billion KRW | -6.52% |
| 2020 Q2 | 6.38 Billion KRW | -1.12% |
| 2020 Q4 | 15.68 Billion KRW | -2.11% |
| 2019 Q4 | 6.9 Billion KRW | 84.88% |
| 2019 FY | 6.9 Billion KRW | 0.0% |
| 2019 Q3 | 3.73 Billion KRW | -4.25% |
| 2019 Q2 | 3.9 Billion KRW | 431.1% |
| 2019 Q1 | 734.87 Million KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2016 FY | - KRW | -100.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q1 | - KRW | -100.0% |
| 2015 Q4 | 2 Billion KRW | -50.0% |
| 2015 Q3 | 4 Billion KRW | 0.0% |
| 2015 Q2 | 4 Billion KRW | 0.0% |
| 2015 Q1 | 4 Billion KRW | 0.0% |
| 2015 FY | 2 Billion KRW | -50.0% |
| 2014 Q1 | 6 Billion KRW | 0.0% |
| 2014 FY | 4 Billion KRW | -33.33% |
| 2014 Q4 | 4 Billion KRW | -33.33% |
| 2014 Q3 | 6 Billion KRW | 0.0% |
| 2014 Q2 | 6 Billion KRW | 0.0% |
| 2013 Q4 | 6 Billion KRW | 0.0% |
| 2013 FY | 6 Billion KRW | -40.0% |
| 2013 Q1 | 10 Billion KRW | 0.0% |
| 2013 Q2 | 6 Billion KRW | -40.0% |
| 2013 Q3 | 6 Billion KRW | 0.0% |
| 2012 Q2 | 23.5 Billion KRW | 27.03% |
| 2012 Q1 | 18.5 Billion KRW | -35.09% |
| 2012 Q4 | 10 Billion KRW | -33.33% |
| 2012 FY | 10 Billion KRW | -64.91% |
| 2012 Q3 | 15 Billion KRW | -36.17% |
| 2011 Q4 | 28.5 Billion KRW | 0.0% |
| 2011 Q1 | 38.5 Billion KRW | -9.94% |
| 2011 FY | 28.5 Billion KRW | -33.33% |
| 2011 Q3 | 28.5 Billion KRW | -25.97% |
| 2011 Q2 | 38.5 Billion KRW | 0.0% |
| 2010 Q3 | 46.12 Billion KRW | 6.96% |
| 2010 FY | 42.75 Billion KRW | 35.17% |
| 2010 Q4 | 42.75 Billion KRW | -7.32% |
| 2010 Q1 | 31.62 Billion KRW | 0.0% |
| 2010 Q2 | 43.12 Billion KRW | 36.36% |
| 2009 Q2 | 31.22 Billion KRW | -6.34% |
| 2009 Q1 | 33.33 Billion KRW | 41.6% |
| 2009 FY | 31.62 Billion KRW | -5.13% |
| 2009 Q3 | 31.11 Billion KRW | -0.36% |
| 2008 Q4 | 23.54 Billion KRW | 527.94% |
| 2008 Q1 | 6.16 Billion KRW | -4.26% |
| 2008 Q2 | 3.95 Billion KRW | -35.81% |
| 2008 FY | 33.33 Billion KRW | 441.03% |
| 2008 Q3 | 3.74 Billion KRW | -5.21% |
| 2007 FY | 6.16 Billion KRW | -36.86% |
| 2007 Q2 | 6.98 Billion KRW | 0.0% |
| 2007 Q3 | 6.7 Billion KRW | -3.92% |
| 2007 Q4 | 6.43 Billion KRW | -4.08% |
| 2006 FY | 9.75 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -22.453% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 93.025% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 87.37% |
| HANDOK Inc. | 300.01 Billion KRW | 83.915% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -57.378% |
| Yuhan Corporation | 230.07 Billion KRW | 79.026% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 88.135% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -8003.529% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 91.577% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -3639.19% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 43.336% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -11.514% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 46.669% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -81.869% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -22.453% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -20164.633% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 78.558% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 73.339% |
| JW Holdings Corporation | 554.58 Billion KRW | 91.299% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 77.848% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 78.042% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 71.661% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -4.559% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -23.085% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 72.563% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 43.206% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -22.453% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 79.522% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 89.726% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 71.661% |
| Yuhan Corporation | 230.07 Billion KRW | 79.026% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 72.112% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 27.85% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 89.686% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 71.661% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 59.326% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -19.624% |
| CKD Bio Corp. | 146.92 Billion KRW | 67.157% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 66.96% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -7535.034% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -4.559% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 89.69% |
| Boryung Corporation | 204.21 Billion KRW | 76.37% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 39.215% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 43.336% |
| JW Lifescience Corporation | 46.31 Billion KRW | -4.194% |